5.3.24
2024 AD/PD conference
7.11.23
Amyl Therapeutics receives additional €5M funding
4.9.22
Amyl Team at the International Society on amyloidosis
We are excited to announce that Pierre Vandepapeliere, our CEO and Damien Toulorge, our Chief Scientific Officer, will be attending BioEurope 2024. This premier event brings together leaders in the biopharmaceutical industry to discuss innovation, partnership opportunities, and the future of biotech.
We look forward to engaging with fellow professionals, sharing insights, and exploring collaborations that will drive Amyl’s mission forward. If you're attending, don't hesitate to connect with Pierre and Damien!